Healthians posts first annual profit as FY26 operating revenue rises 35.7% to Rs 357 crore
At-home diagnostics platform Healthians reported FY26 net profit of Rs 5.4 crore, reversing a Rs 4.77 crore loss in FY25. Diagnostics contributed 99% of operating revenue as the company expanded across 250-plus cities.
What happened
Indian at-home diagnostics platform Healthians reported its first annual profit in FY26, with operating revenue rising 35.7% to Rs 357 crore. Diagnostics
Key facts
- FY26 revenue from operations: Rs 357 crore, up 35.7% from Rs 263 crore in FY25
- FY26 total revenue: Rs 362 crore versus Rs 270 crore in FY25
- FY26 net profit: Rs 5.4 crore versus FY25 loss of Rs 4.77 crore
- Diagnostics revenue: Rs 353 crore, 99% of operating revenue
- FY26 total expenditure: Rs 364 crore, up 32.4%
- Employee benefits: Rs 134 crore, up 28%
- Material costs: Rs 109 crore
- Marketing expense: Rs 44 crore
- Accumulated losses: Rs 976 crore
- EBITDA margin: 2.20%
- ROCE: -4.86%
- Current assets: Rs 112.5 crore
- Funding raised to date: around $75 million
- Operations across more than 250 cities
- More than 10 crore tests conducted
Why this matters
Healthians’ national diagnostics footprint and newly profitable platform strengthen its appeal for hospital, insurer, pharmacy and preventive-care partnerships that can diversify revenue.
What to watch
- Whether FY27 revenue growth stays above 25% while net profit and operating margins continue to improve.
- Marketing expense, discount intensity and customer-acquisition-cost trends relative to repeat-order rates.
- Expansion of owned versus partner laboratory capacity, sample turnaround times and service-quality indicators in new cities.
- Growth in B2B, insurance and corporate-health revenue, which would diversify the 99% diagnostics-led revenue base.
- Competitive pricing and home-collection investments by established diagnostic chains and digital-health platforms.
- Cash flow from operations, receivable days and any new capital raise following the shift to profitability.
- Prioritize repeat preventive-care customers, family subscriptions and chronic-disease monitoring packages to reduce dependence on one-time discounted test orders.
- Use FY26 profitability to selectively expand collection infrastructure and laboratory capacity in high-density cities rather than pursuing broad, subsidy-heavy geographic expansion.
- Increase employer, insurer, hospital and clinician partnerships to lower customer-acquisition costs and create steadier B2B/B2B2C volumes.
- Defend margins through route-density optimization, automated report workflows, bundled test panels and tighter control of promotional discounts.
- Potentially use the profitable milestone to improve fundraising terms, pursue strategic partnerships or evaluate acquisition of regional diagnostic capabilities.